A therapeutic trial of the use of penicillin V or erythromycin with or without rifampin in the treatment of psoriasis - 06/10/17
Résumé |
Background: After the publication of an uncontrolled trial of nine patients with streptococcus-associated psoriasis who appeared to benefit from a course of oral penicillin or erythromycin with the addition of rifampin in the last 5 days, we wished to confirm or refute the validity of this observation.
Objective: Our purpose was to confirm the effectiveness of antibiotics in the treatment of streptococcus-associated psoriasis.
Methods: Twenty patients were placed randomly into two groups. One group was given penicillin or erythromycin for 14 days with a placebo added during the last 5 of the 14 days. The other group received the same medication with the addition of rifampin in the last 5 days. Results. Although all the patients studied met the criteria of the reported preliminary study, we were unable to detect any evidence of improvement in their psoriasis.
Conclusion: There was no apparent benefit for patients with streptococcus-associated psoriasis from a course of oral penicillin or erythromycin with the addition of rifampin in the last 5 days in a 14-day trial.
Le texte complet de cet article est disponible en PDF. Supported by Merrell Dow Co. |
Vol 26 - N° 3
P. 458-461 - mars 1992 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?